Results 51 to 60 of about 368,793 (264)

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor [PDF]

Oncogene, 2010
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib are effective therapies against mutant non-small cell lung cancers (NSCLCs). Treatment is limited by the development of resistance in part explained by the gain of a secondary EGFR mutation, T790M, at the gatekeeper residue.
D, Ercan, K, Zejnullahu, K, Yonesaka, Y, Xiao, M, Capelletti, A, Rogers, E, Lifshits, A, Brown, C, Lee, J G, Christensen, D J, Kwiatkowski, J A, Engelman, P A, Jänne   +12 more
openaire   +2 more sources

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Effects of DPP4 inhibitors on renal outcomes in diabetes mellitus: A systematic review and meta-analysis

Indian Journal of Endocrinology and Metabolism, 2021
Objectives: This meta-analysis of randomized clinical trials (RCT) intends to evaluate the efficacy of DPP4 Inhibitors (DPP4I) compared with placebo, other antidiabetics (or DPP4I) on renal outcomes, adverse events (AEs), and all-cause mortality. Methods:
Saikat K Dalui, Raja Chakraverty, Nafisha Yasmin, Smita Pattanaik, Kaushik Pandit, Suparna Chatterjee   +5 more
doaj   +1 more source

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors [PDF]

Journal of Thoracic Oncology, 2013
Non-small-cell lung cancers (NSCLCs) containing EGFR mutations are exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This is the case of the most common EGFR mutations affecting exon 18 (G719X), 19 (inframe deletions), and 21 (L858R and L861Q). However, the frequency of compound (i.e., double or complex)
Kobayashi, Susumu, Canepa, Hannah M., Bailey, Alexandra S., Nakayama, Sohei, Yamaguchi, Norihiro, Goldstein, Michael A., Huberman, Mark S., Costa, Daniel B.   +7 more
openaire   +2 more sources

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

MONITORING OF EGFR MUTATIONS IN THE CIRCULATING TUMOR DNA FROM BLOOD PLASMA OF PATIENTS WITH NON-SMALL CELL LUNG CANCER

Сибирский онкологический журнал, 2018
Activating mutations of EGFR are associated with sensitivity of non-small cell lung cancer (NSCLC ) to tyrosine kinase inhibitors (TKI). Liquid biopsy using circulating cell-free tumor DNA (cfDNA) is proposed in cases when formalin fixed paraffin ...
V. A. Shamanin, I. V. Karpov, P. А. Gervas, N. V. Cherdyntseva, E. I. Simolina, V. V. Kozlov, S. P. Kovalenko   +6 more
doaj   +1 more source

The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast

Türk Patoloji Dergisi, 2020
Objective: Basal markers [cytokeratin 5/6 (CK5/6) and epidermal growth factor receptor (EGFR)] are used in identifying the basal-like breast carcinoma subtype, which is associated with a poor prognosis.
Fikret DIRILENOĞLU, Demet ARIKAN ETIT, Halil TAŞKAYNATAN, Ferhan ELMALI   +3 more
doaj   +1 more source

EGFR Mutation Status and PD-L1 Expression in Patients ≤40 Years Old with NSCLC

Zhongliu Fangzhi Yanjiu, 2022
Objective To retrospectively analyze the clinical data of 47 young NSCLC patients mutation style of EGFR and PD-L1 expression in tumor cells, to understand their clinicopathological and molecular characteristics.
HU Mingming, LIU Zichen, ZHANG Hongmei, LU Baohua, LI Jie, WANG Qunhui, HU Fanbin, LIN Haifeng, LI Baolan, ZHANG Tongmei   +9 more
doaj   +1 more source

EGFR-targeted therapy

Experimental Cell Research, 2011
Anti-Epidermal Growth Factor Receptor (EGFR) therapies have been recently developed for the treatment of multiple cancer types. At the time when they were introduced in clinical practice, there was little knowledge of the molecular bases of tumor sensitivity and resistance to these novel targeted compounds.
Vecchione L, Jacobs B, Normanno N, CIARDIELLO, Fortunato, Tejpar S.   +4 more
openaire   +4 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source